多发性骨髓瘤细胞依赖DDI2/NRF1介导的蛋白酶体应激反应生存
多发性骨髓瘤(MM)细胞因基线蛋白毒性而依赖蛋白酶体应激反应。研究发现MM细胞存在基线NRF1激活并依赖DDI2生存,DDI2敲除在体内外对MM细胞有细胞毒性,并阻断NRF1切割与核转位,导致不可逆蛋白酶体抑制后蛋白酶体活性恢复受损,从而增加对蛋白酶体抑制剂的敏感性。回补野生型而非催化失活型DDI2可完全挽救这些表型。DDI2是MM中未被探索的潜在分子靶点。
要点
- MM细胞存在基线NRF1激活并依赖DDI2生存。
- DDI2敲除在体内外对MM细胞有细胞毒性。
- DDI2敲除阻断NRF1切割与核转位,增加对蛋白酶体抑制剂的敏感性。
核心结论
- DDI2是MM中未被探索的潜在分子靶点,可通过破坏蛋白酶体应激反应加重蛋白毒性。
研究设计与样本
- 采用MM细胞系进行体外研究及体内实验,结合DDI2敲除、回补野生型或催化失活型DDI2以及蛋白结构功能研究。
主要发现
- MM细胞存在基线NRF1激活并依赖DDI2生存。
- DDI2敲除在体外和体内对MM细胞有细胞毒性。
- DDI2敲除阻断NRF1切割与核转位,导致不可逆蛋白酶体抑制后蛋白酶体活性恢复受损。
- 回补野生型而非催化失活型DDI2可完全挽救上述表型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) cells suffer from baseline proteotoxicity as the result of an imbalance between the load of misfolded proteins awaiting proteolysis and the capacity of the ubiquitin-proteasome system to degrade them. This intrinsic vulnerability is at the base of MM sensitivity to agents that perturb proteostasis, such as proteasome inhibitors (PIs), the mainstay of modern-day myeloma therapy. De novo and acquired PI resistance are important clinical limitations that adversely affect prognosis. The molecular mechanisms underpinning PI resistance are only partially understood, limiting the development of drugs that can overcome it. The transcription factor NRF1 is activated by the aspartic protease DNA damage inducible 1 homolog 2 (DDI2) upon proteasome insufficiency and governs proteasome biogenesis. In this article, we show that MM cells exhibit baseline NRF1 activation and are dependent upon DDI2 for survival. DDI2 knockout (KO) is cytotoxic for MM cells, both in vitro and in vivo. Protein structure-function studies show that DDI2 KO blocks NRF1 cleavage and nuclear translocation, causing impaired proteasome activity recovery upon irreversible proteasome inhibition and, thereby, increasing sensitivity to PIs. Add-back of wild-type, but not of catalytically dead DDI2, fully rescues these phenotypes. We propose that DDI2 is an unexplored promising molecular target in MM by disrupting the proteasome stress response and exacerbating proteotoxicity.
引用
- Chen T, Ho M, Briere J, et al. Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival. Blood Adv. 2022. PMID: 34649278. doi:10.1182/bloodadvances.2020003820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。